Journal of the American Psychiatric Nurses Association

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vreeland, B.
Right arrow Articles by Kim, E.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of the American Psychiatric Nurses Association, Vol. 10, No. 3 suppl, S17-S24 (2004)
DOI: 10.1177/1078390304265287
© 2004 American Psychiatric Nurses Association

Managing the Clinical Consequences of Psychiatric Illness and Antipsychotic Treatment: A Discussion of Obesity, Diabetes, and Hyperprolactinemia

Betty Vreeland

University of Medicine and Dentistry of New Jersey (UMDNJ); UMDNJ-University Behavioral HealthCare; UMDNJ-School of Nursing; UMDNJ-Robert Wood Johnson Medical School in Piscataway, New Jerseyvreelael{at}umdnj.edu

Edward Kim

Adult Services for the University of Medicine and Dentistry of New Jersey (UMDNJ); University Behavioral HealthCare; UMDNJ-Robert Wood Johnson Medical School, in Piscataway, NJ.

Many individuals who suffer from serious and persistent mental illness also have co-occurring physical problems that are frequently misdiagnosed, underdiagnosed, or undertreated. Tragically, this population loses between 8 and 20 years of life expectancy when compared to a nonpsychiatric population. Hyperglycemia, diabetes, and weight gain have long been established as correlating with mental illness and psychotropic medications, leaving it difficult to identify which condition came first. Hyperprolactinemia is an additional consequence of select antipsychotic therapies that results in endocrine and sexual disturbances. Clinicians need to understand how to assess and manage the health risks associated with psychiatric conditions and their treatments. The psychiatric nurse is a key member of the health care team whose holistic framework can afford an opportunity to bridge the gap between mental and physical health. This article discusses the overall assessment and management of psychotropic-associated weight gain, obesity, type 2 diabetes, and hyperprolactinemia in patients with schizophrenia and bipolar disorder.

Key Words: psychotropic-associated weight gain • obesity • type 2 diabetes • hyperprolactinemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Psychiatr Nurses AssocHome page
S. Simmons-Alling and S. Talley
Bipolar Disorder and Weight Gain: A Multifactorial Assessment
Journal of the American Psychiatric Nurses Association, January 1, 2008; 13(6): 345 - 352.
[Abstract] [PDF]